CARGO Therapeutics, Inc. - Common Stock (CRGX)
4.1250
+0.3250 (8.55%)
CARGO Therapeutics, Inc. is a biotechnology company focused on the development of innovative therapies for treating cancer and other serious diseases
The company specializes in harnessing and engineering cellular therapies, particularly in the field of immuno-oncology, to create targeted treatment options that aim to enhance the body’s natural ability to fight cancer. By leveraging advanced technologies and a deep understanding of the immune system, CARGO Therapeutics is committed to advancing groundbreaking treatments that can improve patient outcomes and provide new hope for those affected by difficult-to-treat conditions.
Previous Close | 3.800 |
---|---|
Open | 4.500 |
Bid | 4.120 |
Ask | 4.130 |
Day's Range | 4.040 - 4.550 |
52 Week Range | 3.000 - 32.79 |
Volume | 3,511,981 |
Market Cap | - |
PE Ratio (TTM) | - |
EPS (TTM) | - |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 591,644 |
News & Press Releases
Wondering what's happening in Wednesday's pre-market session? Find an overview in this article.
Via Chartmill · March 19, 2025
Via Benzinga · March 19, 2025
Via Benzinga · March 19, 2025
Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session.
Via Chartmill · March 18, 2025
Via Benzinga · March 18, 2025
- Development of CRG-023 and allogeneic platform suspended; further reduction in force (RIF) of approximately 90% to preserve cash and maximize shareholder value -
By Cargo Therapeutics, Inc. · Via GlobeNewswire · March 18, 2025

Biotech remains a high-risk, high-reward sector, and this month’s top draws reflect retail’s appetite for stocks with major clinical and regulatory catalysts.
Via Stocktwits · January 31, 2025

Unusual volume stocks are being observed in Friday's session.
Via Chartmill · January 31, 2025

Here are the top movers in Thursday's session, showcasing the stocks with significant price changes.
Via Chartmill · January 30, 2025

Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements.
Via Chartmill · January 30, 2025

Let's delve into the US markets on Thursday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
Via Chartmill · January 30, 2025

Let's have a look at what is happening on the US markets before the opening bell on Thursday. Below you can find the top gainers and losers in today's pre-market session.
Via Chartmill · January 30, 2025

Via Benzinga · January 30, 2025

Via Benzinga · January 30, 2025

Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
Via Chartmill · January 29, 2025

Via Benzinga · January 30, 2025

The DJS Law Group announces that it is investigating claims on behalf of investors of CARGO Therapeutics, Inc. (“CARGO” or “the Company”) (NASDAQ: CRGX) for violations of the securities laws.
By DJS Law Group · Via Business Wire · January 29, 2025

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CARGO Therapeutics, Inc. (“CARGO” or “the Company”) (NASDAQ: CRGX) for violations of the securities laws.
By The Schall Law Firm · Via Business Wire · January 29, 2025

SAN CARLOS, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (Nasdaq: CRGX), a clinical-stage biotechnology company advancing next generation, potentially curative cell therapies for cancer patients, today announced that it has elected to discontinue FIRCE-1, a Phase 2 clinical study of firi-cel for patients with large B-cell lymphoma (LBCL) whose disease relapsed or was refractory (R/R) to CD19 CAR T-cell therapy. In-line with this decision, the Company will reduce its workforce to extend cash runway and prioritize the advancement of CRG-023 to Phase 1 proof-of-concept data as well as its novel allogeneic platform.
By Cargo Therapeutics, Inc. · Via GlobeNewswire · January 29, 2025

- 71 patients dosed in the potentially pivotal Phase 2 clinical study of firicabtagene autoleucel (firi-cel); Interim analysis results expected to be reported in 1H’25 -
By Cargo Therapeutics, Inc. · Via GlobeNewswire · January 10, 2025

Via Benzinga · December 30, 2024

SAN CARLOS, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ: CRGX), a clinical-stage biotechnology company positioned to advance next-generation, potentially curative cell therapies for cancer patients, today announced that the company will participate in the 43rd Annual J.P. Morgan Healthcare Conference, taking place January 13-16, 2025, in San Francisco, California.
By Cargo Therapeutics, Inc. · Via GlobeNewswire · December 17, 2024

- 57 patients dosed in the potentially pivotal Phase 2 clinical study, FIRCE-1 of firicabtagene autoleucel (firi-cel); on track for interim analysis in 1H25 -
By Cargo Therapeutics, Inc. · Via GlobeNewswire · November 12, 2024